Applied Dna Sciences Q3 2026 Earnings Report

Applied Dna Sciences EPS Results

• Actual EPS: -$0.57
• Consensus EPS: N/A
• Beat/Miss: N/A
• One Year Ago EPS: N/A

Applied Dna Sciences Revenue Results

• Actual Revenue: $0.61 million
• Expected Revenue: N/A
• Beat/Miss: N/A
• YoY Revenue Growth: N/A

Applied Dna Sciences Announcement Details

• Quarter: Q3 2026
• Date: 8/13/2026
• Time: After Market Closes
• Conference Call Date: N/A
• Conference Call Time: N/A

Applied Dna Sciences (NASDAQ:BNBX) is a U.S.-based biotechnology company that develops and commercializes molecular-level solutions for product authentication, supply chain security and forensic identification. The company’s technologies apply unique DNA markers and laboratory testing methods to tag, track and verify the authenticity of goods and materials, with the goal of combating counterfeiting, diversion and fraud across complex supply chains.

Central to Applied DNA’s offering is a suite of proprietary DNA-based markers and associated assays that can be incorporated into inks, fibers, coatings and other substrates to create tamper-evident, forensic-grade identifiers. The company supports those markers with laboratory services—using PCR and sequencing techniques—to analyze samples, produce digital chain-of-custody reports and provide verification for customers. Its business model includes product sales, licensing and contract testing or integration work tailored to customer requirements.

Applied DNA’s solutions are used by organizations that need robust provenance and anti-counterfeiting measures, including manufacturers, distributors and entities in regulated industries. The company provides services to customers in the United States and internationally, seeking to address global supply-chain vulnerabilities by combining intellectual property, laboratory capability and field-deployable tagging technologies. Applied DNA Sciences is publicly traded on the NASDAQ.